

Percutaneous Mitral Valvuloplasty

Ștefan Moț M.D.

Heart Institute "N.Stancioiu"

Cluj-Napoca, România

- I have nothing to disclose

The Burden of Valve Disease

Euro Heart Survey

Prevalence

Survival

Figure 1B






Figure 2B



(Nkomo. *Lancet* DOI:10.1016)


Distribution and etiology of valvular heart disease EURO HEART SURVEY

Distribution of Valvular Heart Diseases in the Euro Heart Survey



(Jung et al. Eur Heart J 2003;24:1244-53)

Aetiologies of Single Valvular Heart Diseases in the Euro Heart Survey



(Jung et al. Eur Heart J 2003;24:1244-53)

Guidelines Slide-set © 2007 European Society of Cardiology




VHD Guidelines Slide-set © 2007 European Society of Cardiology



Indications for percutaneous mitral commissurotomy

	Class	Level
PMC is indicated in symptomatic patients with favourable characteristics.	I	B
PMC is indicated in symptomatic patients with contraindication or high risk for surgery.	I	C
PMC should be considered as initial treatment in symptomatic patients with unfavourable anatomy but without unfavourable clinical characteristics.	Ila	C
PMC should be considered in asymptomatic patients without unfavourable characteristics and: <ul style="list-style-type: none"> • high thromboembolic risk (previous history of embolism, dense spontaneous contrast in the left atrium, recent or paroxysmal atrial fibrillation), and/or • high risk of haemodynamic decompensation (systolic pulmonary pressure > 50 mmHg at rest, need for major non-cardiac surgery, desire for pregnancy). 	Ila	C

Management of clinically significant mitral stenosis



European Heart Journal 2012 - doi:10.1093/eurheartj/ehs109 &
 European Journal of Cardio-Thoracic Surgery 2012 -
 doi:10.1093/ejcts/ezs455).

Timing for intervention

PTMC: BEST CHOICE FOR:


- Patients with contraindications to or high risk for surgery(I C)
- Patients with favorable presenting characteristics(I B)
 - Predictors of poor late results:
 - Age $p=0,003$
 - Rhythm before PTMC $p=0,001$
 - Mitral regurgitation after PTMC $p<0,004$
 - Gradient after PTMC $p=0,0001$
 - Valve area after PTMC $p=0,001$

lung, Circulation, 1999, 99
VHD ESC Guidelines, 2007

Echocardiographic score

Wilkins score: 4 Factors

1. 0----4 Degree of leaflet rigidity
2. 0----4 Severity of leaflet thickening
3. 0----4 Amount of leaflet calcification
4. 0----4 Extent of subvalvular thickening and calcification




Wilkins, Br. Heart J. 1988, 60
Palacios, Circulation 2002, 105



Choice of patients; challenging issues 1

- PTMC is to be considered as an initial treatment in symptomatic patients with unfavorable anatomy but otherwise favorable clinical characteristics (IIa C)

PTMC can be preferred as initial procedure in patients with mild to moderate calcification and otherwise favorable characteristics
In case of massive calcification valve replacement is indicated



Cannan, J. Am. Coll. Cardiol. 1997, 29



Choice of patients; challenging issues 2

Which patients with few or no symptoms are candidates for balloon valvuloplasty?

MS < 1.5 cm², favorable presenting parameters, experienced team and:

- Increased thromboembolic risk
 - previous embolism
 - dense contrast in the left atrium
 - recent onset of recurrent paroxysmal atrial fibrillation

OR

- High risk for hemodynamic decompensation
 - pulmonary hypertension (50 mmHg-rest; 60 mmHg-stress)
 - desire of pregnancy
 - need for major extracardiac surgery

Contraindications for balloon valvuloplasty

- Valve area $> 1,5\text{cm}^2$
- Left atrial thrombus
- Mitral regurgitation $> 2/4$
- Massive calcification or bicomissural calcification
- Absence of commissural fusion
- Severe aortic valve disease or severe combined tricuspid stenosis and regurgitation
- Concomitant coronary artery disease requiring by-pass surgery


Left atrial thrombus

- Present in 32% of patients not previously treated with anticoagulants(Sillarnks,2004)
- Detection of thrombus is easily done with TEE
- Factors influencing disappearance of LA thrombus after 6 months of warfarin:
 - Thrombus size $< 1.6 \text{ cm}^2$
 - Localization in the left appendage
 - NYHA class I/II
 - Less marked spontaneous contrast
 - Maintenance of INR $> 2,5$
- Resolution or organization of thrombus 32-94%
- Mobile thrombus on the interatrial septum remain a total contraindication for PTMC

Shaw,Heart,2005,91


Techniques of PTMC

- Balloon Commissurotomy
 1. Inoue technique
 2. Double balloon technique
- Metallic Commissurotomy



Technique of percutaneous balloon mitral valvuloplasty The INOUE technique


- Femoral access (venous and arterial)
- Right atrial angiography (optional) with levogram



The Inoue Technique






The transeptal puncture: Mullins sheath and Brockenbrough needle
(*fossa ovalis*)

TEE guidance





The INOUE technique

- Balloon advancement in LA and through the mitral valve in the LV
- Stepwise dilatation with hemodynamic and echocardiographic measurements



Technique of balloon mitral valvuloplasty




Step-wise dilatation


Immediate outcome

Achievement of
a mitral valve
area $\sim 2 \text{ cm}^2$




PREPBVM



POSTPBVM



Immediate drop
in transmitral
gradient




Short term outcome, Complications:

- Agravation of mitral regurgitation $>3/4$
- Left-Right resting shunt
- LA or LV perforation with tamponade
- Embolic accidents
- Acute MI

Immediate Results

Good Immediate Results ($V.A. \geq 1.5 \text{ cm}^2$ without $MR > 2/4$)
3284 /3709 patients (88.5%)




(Madjoub. ESC 2006)

Long term results

Survival at 4 years=84%

Event free survival at 4 years (death,surgery,re-PTMC=60%)

Continuous loss in mitral valve area over time with $>0,3\text{cm}^2$ in 7 years



Experience in Heart Institute of Cluj-Napoca


2005-2010

- 198 patients with mitral stenosis underwent percutaneous balloon valvuloplasty
- 167 patients-long term study group-all with clinical and echocardiographic follow up between jan-mar 2014 (4-9 years/average 5.8)

PARAMETER	AVERAGE	LIMITS
Age	44.9 ± 7.21	19 - 65
Gender	3/1 female/male	
Mitral valve area	1.10 ± 0.20	0.5 – 1.6
Peak MV gradient	16.12 ± 5.06	6.98 - 35
Mean MV gradient	9.29 ± 3.44	3 - 25
Sistolic pulmonary pressure	48.56 ±15.10	12 - 125


Experience in Heart Institute Cluj-Napoca

COMORBIDITY	No.	%
Mitral regurgitation(<2/4)	150	76.12
Comissural calcification	75	38.8
Aortic valve disease	17	59.7
Left atrial thrombus (after coumadine)	15	7.46
Coronary heart disease	9	4.48
NYHA class \geq III	125	62.69




Long term follow up

GRADIENT




MV AREA



Long term follow up


Patients alive, with or without surgery - 139



■ Without restenosis ■ Death ■ Prothesis ■ Restenosis

Long term follow up

MVA > 1,5 cm² and NYHA class ≤ II ~80%



□ With restenosis ■ Without restenosis

CONCLUSIONS

- Percutaneous mitral valvuloplasty is very effective for short, medium and also long term follow up
- The decision to recommend a patient mitral valvuloplasty depends of the various factors that are influencing the outcome
- Particullary in young patients reintervention is possible to be necessary during long term follow up